ClinicalTrials.gg
CompletedNCT02666846Updated Jan 27, 2021Results posted

Assess the Efficacy and Safety in Volunteers of DCF100, TIB200 and SPR300 vs. Placebo and Control(s) in a UV Pain Model

A Phase 1 interventional study of Ibuprofen and Diclofenac in Pain, sponsored by Futura Medical Developments Ltd.. Completed at 1 site in United Kingdom. Open to male participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2021-01-27.

Sponsored by Futura Medical Developments Ltd. · Phase 1, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
60
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 86 studies testing ibuprofen in Pain — 6 open to participants now, 6 under way, none of them phase 3. Ibuprofen · Pain.

Enrollment
57th of 86
60 · median 100
Started
2015
with 6 others
Phase 1
9 of 86
none open now
Registered
49th of 86
by date

Among the 86 studies testing ibuprofen in Pain, this one is the 57th largest by enrollment, is one of 7 that started in 2015, is one of 9 in phase 1, and was the 49th registered.

Pain

10,069 studies on the registry are indexed under Pain; 1,651 are open to participants now.

Browse Pain studies →

Open to participants now

6 of the 86 studies testing ibuprofen in Pain are open now, in 4 countries. Recruiting first, the newest first:

1 more — sign in →

By country, each count listing its studies:

All 6 open studies →

About ibuprofen

Ibuprofen: first FDA approval 1974 (MOTRIN), first EMA approval 2004. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 928 Pain studies recruiting now, 383 (41%) set no upper age limit and 434 (47%) stop at 75 or younger; 146 take children under 18; 222 take healthy volunteers.

This study: 18 Years to 65 Years · male · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 86 studies testing ibuprofen in Pain, or all of them as a file.
02

Study summary

This is a randomised, double blind, cross over clinical study in healthy human volunteers (including pharmacokinetic [PK] sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort of 20) to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain.

Read the detailed description

This is a randomised, double blind, cross over clinical study in healthy human volunteers, including pharmacokinetic (PK) sampling and laser Doppler assessment of local blood flow in a subset of up to 6 subjects per cohort, to assess the efficacy and safety of three different topical analgesics (DCF100, TIB200 and SPR300) versus placebo and active control(s) in a model of UV-induced inflammatory pain. The study will consist of 3 cohorts of subjects (n=20 subjects per cohort). Subjects of each cohort will receive test and reference products (no reference product for Cohort 3) of one investigational medicinal product (IMP) and a placebo.

Test Products:

Cohort 1: Ibuprofen, TIB200 gel (10%, w/w) Cohort 2: Diclofenac, DCF100 gel (2% or 4%, w/w) Cohort 3: Methyl-salicylate and Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate to Menthol)

Reference Products:

Cohort 1: Ibuprofen, Nurofen Max Strength gel (10%, w/w), Ibuprofen, Nurofen, oral tablet (400 mg) Cohort 2: Voltaren Emulgel (2%), Voltarol oral tablet (50 mg)

Placebo:

All Cohorts:Test product matching vehicle gel.

Pharmacodynamic tests and PK blood draws will be performed at: pre-dose, 1, 2, 4, and 6 hours post dose for all treatment cohorts and treatment days (PK blood sampling in up to 6 subjects per cohort only).

Safety will be evaluated by the incidence of local and systemic treatment-emergent adverse events (TEAEs) reported after each treatment. Safety assessments will also include vital signs, 12-Lead Electrocardiograms (ECGs), laboratory tests and a physical examination at Screening and the Follow-up visit.

03

Conditions studied

  • Pain

Browse trials for

Keywords

  • UVB Pain Model
  • PK
  • Topical
  • NSAIDs
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
Male
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Were able to provide written .
  2. Male between 18 and 65 years old, inclusive, at the time of screening.
  3. Good general health as ascertained by detailed medical history and physical examination.
  4. (BMI) ≥18 and ≤29 kg/m2 (BMI = weight/height2), at the time of screening.
  5. No abnormalities in 12-lead as per PI's judgement, e.g., absence of cardiac rhythm disorder, in particular bradycardia (\<40 beats per minute), conduction abnormalities such as atrioventricular block, absence of active ischemia (such as unstable angina pectoris) or recent myocardial infarction, no interval >450 milliseconds, no QRS complex ≥120 milliseconds, at Screening.
  6. No clinically relevant abnormalities in results of laboratory tests as per PI's judgement; in particular, no significant liver impairment defined as (AST), alanine aminotransferase (ALT) 1.5x (ULN); no significant kidney impairment defined as serum creatinine 2x ULN; abnormal thyroid function as defined by thyroid-stimulating hormone (TSH) and total thyroxin (T4) (TSH within range 0.27 to 4.2 mIU/L, total T4 within range 59 to 154 nmol/L).
  7. Had a skin type II or III (Fitz Patrick classification).
  8. Non-smokers or ex-smokers for at least 6 months prior to the Screening Visit, as confirmed by a urine cotinine test.
  9. Subjects were able to communicate well with the PI/designee. -

Exclusion criteria

Exclusion Criteria:

  1. History of to the IMP or any of the or to medicinal products with similar chemical structures.
  2. Presence of any acute or chronic disease which could interfere with the subject safety during the study, expose the subject to undue risk, limit the biological sampling (e.g., blood collection), interfere with the absorption of the IMP (e.g., active dermatological conditions at the application sites, or ulcers, irritable bowel syndrome) or interfere with the study objectives.
  3. Skin type I, IV, V or VI (Fitzpatrick Classification).
  4. History of chronic pain symptoms (>6 months) or ongoing pain.
  5. Any condition that required regular concomitant medication including herbal products, or predicted need of any concomitant medication from Screening Visit until the end of the study.
  6. Intake of any medication including over the counter (OTC) medication (in particular any pain killers), herbal and dietary supplements such as St John's Wort, vitamins and minerals that could affect the outcome of the study, within 48 hours before the first administration of the product and for the duration of the study.
  7. Use of photosensitising medication, such as phenothiazines, tetracyclines, quinolones, sulphonamides, nalidixic acid, non-steroidal anti-inflammatories, furosemides, hydrochlorothiazides, fibrate, phytotherapeutic drugs (herbal supplements), phenothiazines, quinidines, psoralens and amiodarone within 4 weeks before the first UVB irradiation and for the duration of the study.
  8. Any skin disease, acute or chronic (e.g., psoriasis vulgaris, neurodermatitis) or auto immune diseases associated with increased light sensitisation.
  9. Any active dermatological conditions, local pigmentary disorders, body art (e.g., tattoos), or excessive hair growth at the lower back that might interfere with the study assessments or absorption of the IMP.
  10. History of skin cancer (i.e., melanoma, squamous cell carcinoma or basal cell carcinoma).
  11. History of conditions that increase risk for melanoma (e.g., dysplastic nevus [>5 nevi], xeroderma pigmentosum, Fanconi anaemia, Bloom's syndrome, Werner syndrome, Cockayne syndrome, trichothiodystrophy, or familial mole melanoma syndrome).
  12. History of bleeding disorders, peptic ulceration or gastro intestinal bleeding, heart burn, cardiovascular disease, myocardial infarction or stroke.
  13. Inability to give reproducible HPPT ratings on naïve skin at screening, (defined as HPTT test re-test difference ≥1.0 °C)
  14. Heat pain perception threshold \<40°C or >51°C on naïve skin at Screening.
  15. Supine systolic blood pressure (SBP) \<90 mmHg or >140 mmHg, or supine diastolic blood pressure (DBP) \<50 mmHg or >90 mmHg after 5 minutes supine, at the Screening Visit.
  16. Positive test results for , HCVAb or -1 and/or -2 antibodies at Screening.
  17. Excessive use of caffeine-containing beverages exceeding 500 mg caffeine/day (5 cups of coffee) and the inability to refrain from the use of caffeine-containing beverages during confinement in the Clinical Unit.
  18. Excessive alcohol consumption (regular alcohol intake ≥21 units per week). Use of alcohol 48 hours before any study visit, as confirmed by urine alcohol testing at Screening, Day -2, and with any additional tests at the discretion of the PI.
  19. History in the last year or presence of drug addiction (positive urine drug screen) at Screening and Day -2.
  20. Presence or history of alcohol abuse in the last year, as confirmed by subject's general practitioner (GP).
  21. Blood donation within 8 weeks before the first IMP administration.
  22. Participation in another study with an experimental drug within 3 months before the first dosing day.
  23. Any psychological, emotional problems, any disorder or resultant therapy that was likely to invalidate , or limited the ability of the subject to comply with the protocol requirements.
  24. Unlikely to comply with the protocol requirements, instructions and study-related restrictions; e.g., uncooperative attitude, inability to return for Follow-up visits and improbability of completing the clinical study.
  25. Planned surgery, dental procedure, or hospitalisation from the Screening Visit until the end of the study.
  26. Inability to give written informed consent or to comply fully with the protocol.
  27. Subjects who, in the opinion of the PI, were considered unsuitable for any other reason.

    -

Terms in these criteria, in plain language(12)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Cohort 1: TIB200 gel 10%

    All Cohort 1 participants: TIB200 gel (10%, w/w ibuprofen)

    Drug: Ibuprofen

  • Active comparator
    Cohort 1: Nurofen gel 10%

    All Cohort 1 participants: Nurofen Max Strength gel (10%, w/w ibuprofen)

    Drug: Ibuprofen

  • Active comparator
    Cohort 1: Nurofen tablets

    All Cohort 1 participants: Nurofen oral tablets (2 x 400 mg ibuprofen)

    Drug: Ibuprofen

  • Placebo comparator
    Cohort 1: TIB200 Placebo gel

    All Cohort 1 Participants: TIB200 matching placebo gel

    Drug: Placebo

  • Active comparator
    Cohort 2: DCF100 gel 2%

    All Cohort 2 Participants: DCF100 gel (2% w/w diclofenac)

    Drug: Diclofenac

  • Experimental
    Cohort 2: DCF100 gel 4%

    All Cohort 2 Participants: DCF100 gel (4% w/w diclofenac)

    Drug: Diclofenac

  • Active comparator
    Cohort 2: Voltaren gel 2%

    All Cohort 2 Participants: Voltaren Emulgel (2% diclofenac)

    Drug: Diclofenac

  • Active comparator
    Cohort 2: Voltarol oral tablet

    All Cohort 2 Participants: Voltarol oral tablet (50 mg - diclofenac)

    Drug: Diclofenac

  • Placebo comparator
    Cohort 2: DCF100 Placebo gel

    All Cohort 2 Participants: DCF100 matching placebo gel

    Drug: Placebo

  • Active comparator
    Cohort 3: SPR300 gel (15%:7%)

    All Cohort 3 Participants: Methyl-salicylate / Menthol, SPR300 gel (15%:7%, w/w; ratio of Methylsalicylate / Menthol)

    Drug: Methyl-salicylate / Menthol

  • Placebo comparator
    Cohort 3: SPR300 Placebo gel

    All Cohort 3 Participants: SPR300 matching placebo gel

    Drug: Placebo

Interventions

  • Also known as: TIB200 gel 10%, Nurofen gel 10%, Nurofen tablets

  • Also known as: DCF100 gel 2%, DCF100 gel 4%, Voltaren gel 2%, Voltaren oral tablet

  • DrugMethyl-salicylate / Menthol

    Drug page: Menthol

    Also known as: SPR300 gel (15%/7%)

  • DrugPlacebo

    Also known as: TIB200 placebo gel, DCF100 placebo gel and SPR300 placebo gel

06

What researchers measure

Primary outcomes

  1. Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -

    To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.

    Time frame: 15 minutes before to 6 hours post administration

  2. Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])

    Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging \[flux units\], up to 8 subjects per cohort) - Change from baseline

    Time frame: 15 minutes before to 6 hours post administration

Secondary outcomes

  1. Peak Plasma Concentration (Cmax)

    Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)

    Time frame: 15 minutes before and 1, 2, 4 and 6 hours post administration

  2. Area Under the Plasma Concentration Versus Time Curve

    Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)

    Time frame: 15 minutes before and 1, 2, 4 and 6 hours post administration

  3. Number of Recorded Abnormal Clinical Assessments

    Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter

    Time frame: Estimated study duration for each subject will be approximately 6 weeks

  4. Physical Exams to Ensure Safety and Well Being of the Subjects

    Physical examinations - including assessments of the application site. examination.

    Time frame: Estimated study duration for each subject will be approximately 6 weeks

  5. Adverse Events (AEs)

    Local and systemic Adverse Events (AEs).

    Time frame: Estimated study duration for each subject will be approximately 6 weeks

  6. To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects

    To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects

    Time frame: Estimated study duration for each subject will be approximately 6 weeks

07

Results

Posted Sep 29, 2020

Participant flow

Participant flow — Overall Study
MilestoneCohort 1 (Dosed on Days 1, 2 and 3)Cohort 2 (Dosed on Days 1,2,3 and 4)Cohort 3 (Dosed on Days 1 and 2)
Started202020
Completed202020
Not completed000

Outcome measures

PrimaryHeat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -

To assess the pharmacodynamic effect by Heat Pain Tolerance Test (HPTT) which measured the point at which the heat became painful (degrees centigrade) of three topical analgesics, DCF100, TIB200, and SPR300 versus topical placebo and active topical reference products in a model of UV-induced inflammatory pain.

Time frame:
15 minutes before to 6 hours post administration
Reported as:
Mean · Degrees Centigrade
Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -
Degrees CentigradeCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Heat Pain Tolerance Test (HPTT) Measured the Point at Which the Heat Became Painful - Degrees Centigrade -0.3635 ± 1.02770.7358 ± 1.02770.0887 ± 0.9024-0.1983 ± 0.46160.6679 ± 1.06570.8722 ± 1.04300.7978 ± 0.97800.6835 ± 0.73440.1688 ± 0.72310.3934 ± 1.2384-0.0123 ± 1.0103
PrimaryIntensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])

Intensity of the Ultra Violet B radiation (UVB)-induced erythema (determined by assessment of skin blood flow by laser Doppler imaging \[flux units\], up to 8 subjects per cohort) - Change from baseline

Time frame:
15 minutes before to 6 hours post administration
Reported as:
Least squares mean · Laser doppler imaging (Flux Units)
Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])
Laser doppler imaging (Flux Units)Cohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Intensity of the UVB-induced Erythema (Determined by Assessment of Skin Blood Flow by Laser Doppler Imaging [Flux Units])-313.3879 ± 105.7042-171.5589 ± 96.6485-262.0693 ± 88.5449-95.3974 ± 81.4103-228.3016 ± 183.2260-278.1918 ± 103.7333-198.1408 ± 133.2886-198.1408 ± 211.2754-45.376 ± 104.447612.2265 ± 111.106567.3931 ± 91.092
SecondaryPeak Plasma Concentration (Cmax)

Maximum observed plasma concentration (Cmax), time corresponding to occurrence of Cmax (tmax) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)

Time frame:
15 minutes before and 1, 2, 4 and 6 hours post administration
Reported as:
Mean · ng/ml
Peak Plasma Concentration (Cmax)
ng/mlCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Peak Plasma Concentration (Cmax)11.5 ± 145.15 ± 8.129900 ± 54900 ± 00 ± 00 ± 0772 ± 4680 ± 00 ± 0
SecondaryArea Under the Plasma Concentration Versus Time Curve

Area under the concentration vs. time curve from time zero to 6 hours (AUC0-6h) (up to 6 subjects per cohort only) laser Doppler imaging \[flux units\], up to 6 subjects per cohort)

Time frame:
15 minutes before and 1, 2, 4 and 6 hours post administration
Reported as:
Mean · h*ng/ml
Area Under the Plasma Concentration Versus Time Curve
h*ng/mlCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Area Under the Plasma Concentration Versus Time Curve47.7 ± 64.319.9 ± 33.790000 ± 154000 ± 00 ± 00 ± 01030 ± 4630 ± 00 ± 0
SecondaryNumber of Recorded Abnormal Clinical Assessments

Laboratory assessments - standard clinical trial assessments for clinical chemistry and haematology Listing of individual laboratory measurements by subjects and evaluation of each laboratory parameter

Time frame:
Estimated study duration for each subject will be approximately 6 weeks
Reported as:
Number · Assessments
Number of Recorded Abnormal Clinical Assessments
AssessmentsCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Number of Recorded Abnormal Clinical Assessments00000000000
SecondaryPhysical Exams to Ensure Safety and Well Being of the Subjects

Physical examinations - including assessments of the application site. examination.

Time frame:
Estimated study duration for each subject will be approximately 6 weeks
Reported as:
Number · Abnormalities
Physical Exams to Ensure Safety and Well Being of the Subjects
AbnormalitiesCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Physical Exams to Ensure Safety and Well Being of the Subjects00000000000
SecondaryAdverse Events (AEs)

Local and systemic Adverse Events (AEs).

Time frame:
Estimated study duration for each subject will be approximately 6 weeks
Reported as:
Number · Events
Adverse Events (AEs)
EventsCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
Adverse Events (AEs)55111102031
SecondaryTo Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects

To determine Vital Signs and Electrocardiograms (ECGs) that were abnormal to ensure safety and well being of the subjects

Time frame:
Estimated study duration for each subject will be approximately 6 weeks
Reported as:
Number · Abnormal readings
To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects
Abnormal readingsCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
To Determine Vital Signs and Electrocardiograms (ECGs) That Were Abnormal to Ensure Safety and Well Being of the Subjects00000000000

Adverse events

Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Cohort 1: TIB200 Gel 10%0/20 (0%)0/20 (0%)5/20 (25%)
Cohort 1: Nurofen Gel 10%0/20 (0%)0/20 (0%)5/20 (25%)
Cohort 1: Nurofen Tablets0/20 (0%)0/20 (0%)1/20 (5%)
Cohort 1: TIB200 Placebo Gel0/20 (0%)0/20 (0%)1/20 (5%)
Cohort 2: DCF100 Gel 2%0/20 (0%)0/20 (0%)1/20 (5%)
Cohort 2: DCF100 Gel 4%0/20 (0%)0/20 (0%)1/20 (5%)
Cohort 2: Voltaren Gel 2%0/20 (0%)0/20 (0%)0/20 (0%)
Cohort 2: Voltarol Oral Tablet0/20 (0%)0/20 (0%)2/20 (10%)
Cohort 2: DCF100 Placebo Gel0/20 (0%)0/20 (0%)0/20 (0%)
Cohort 3: SPR300 Gel (15%:7%)0/20 (0%)0/20 (0%)3/20 (15%)
Cohort 3: SPR300 Placebo Gel0/20 (0%)0/20 (0%)1/20 (5%)
Most frequent other events
Showing 10 of 12
Most frequent other events
EventCohort 1: TIB200 Gel 10%Cohort 1: Nurofen Gel 10%Cohort 1: Nurofen TabletsCohort 1: TIB200 Placebo GelCohort 2: DCF100 Gel 2%Cohort 2: DCF100 Gel 4%Cohort 2: Voltaren Gel 2%Cohort 2: Voltarol Oral TabletCohort 2: DCF100 Placebo GelCohort 3: SPR300 Gel (15%:7%)Cohort 3: SPR300 Placebo Gel
ItchingSkin and subcutaneous tissue disorders1/204/200/200/201/200/200/200/200/200/200/20
Pain BurningGeneral disorders1/200/200/201/200/200/200/200/200/202/200/20
Back painMusculoskeletal and connective tissue disorders0/201/200/200/200/200/200/200/200/200/200/20
toothacheGastrointestinal disorders0/200/201/200/200/200/200/200/200/200/200/20
headacheGastrointestinal disorders1/200/200/200/200/200/200/200/200/200/200/20
Hot FlushVascular disorders1/200/200/200/200/200/200/200/200/200/200/20
NauseaGastrointestinal disorders1/200/200/200/200/200/200/200/200/200/200/20
Frequency of Micturation IncreasedRenal and urinary disorders0/200/200/200/200/200/200/201/200/200/200/20
Soft StoolsGastrointestinal disorders0/200/200/200/200/200/200/201/200/200/200/20
Commom ColdInfections and infestations0/200/200/200/200/201/200/200/200/200/200/20

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Cohort 1Cohort 2:Cohort 3Total
<=18 years0000
Between 18 and 65 years20202060
>=65 years0000
Sex: Female, Male
Sex: Female, Male(Participants)Cohort 1Cohort 2:Cohort 3Total
Female0000
Male20202060
Region of Enrollment
Region of Enrollment(participants)Cohort 1Cohort 2:Cohort 3Total
United Kingdom20202020
08

Study locations

1 site
  • PAREXEL EPCU Northwick Park
    Harrow, Middlesex HA1 3UJ, United Kingdom
09

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

10

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2015, a primary completion of May 2015 and a completion of May 2015. It does not say whether these dates are actual or estimated.

Results were first posted in Sep 2020, 5 years 4 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 20, 2016
First posted
Jan 28, 2016
Start
Mar 2015
Primary completionActual
May 2015
CompletionActual
May 2015
Results first posted
Sep 29, 2020
Last update
Jan 27, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 27, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT02666846
Lead sponsor
Futura Medical Developments Ltd.
Collaborators
Parexel
Responsible party
Sponsor
First posted
Jan 28, 2016
Start date
Mar 2015
Primary completion
May 2015
Completion
May 2015
Results posted
Sep 29, 2020
Last update
Jan 27, 2021

Study contacts

Annelize Koch, MBChB
principal investigator · PAREXEL Ltd.

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Ibuprofen · Diclofenac

Start the discussion